Literature DB >> 17613887

Formulation study of oxybutynin patches.

Paola Minghetti1, Francesco Cilurzo, Stefania Pagani, Antonella Casiraghi, Riccardo Assandri, Luisa Montanari.   

Abstract

The present feasibility study was designed to obtain a monolayer patch containing oxybutynin (OXY) avoiding chemical permeation enhancers. The highest flux was obtained with a polydimethylsiloxane matrix patch. Because OXY crystals were detected in the matrix within a week, two amino methylmethacrylate copolymers (Eudragit E or Eudragit RS) were used as OXY crystallization inhibitors. A preliminary in vivo study indicated that flux from the stabilized patches had to be increased about 30-40%. This goal was reached by occlusion with a polyethylene layer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17613887     DOI: 10.1080/10837450701212701

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  1 in total

1.  Induction and inhibition of crystallization in drug-in-adhesive-type transdermal patches.

Authors:  Piyush Jain; Ajay K Banga
Journal:  Pharm Res       Date:  2012-10-24       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.